The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Cabozantinib (C), erlotinib (E) or the combination (E+C) as second- or third-line therapy in patients with EGFR wild-type (wt) non-small cell lung cancer (NSCLC): A randomized phase 2 trial of the ECOG-ACRIN Cancer Research Group (E1512).
 
Joel W. Neal
Consulting or Advisory Role - Clovis Oncology
Research Funding - ArQule; Boehringer Ingelheim; Exelixis; Genentech/Roche; Merck; Nektar; Novartis
 
Suzanne Eleanor Dahlberg
Patents, Royalties, Other Intellectual Property - Patent pending for a statistical model assessing tumor growth (Inst)
 
Heather A. Wakelee
Honoraria - Biocon; Peregrine Pharmaceuticals
Consulting or Advisory Role - Peregrine Pharmaceuticals
Research Funding - Agennix (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Clovis Oncology (Inst); Exelixis (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); Regeneron (Inst); Xcovery (Inst)
Travel, Accommodations, Expenses - Biocon; Peregrine Pharmaceuticals
 
Seena C. Aisner
Consulting or Advisory Role - Bristol-Myers Squibb/Medarex (I)
 
Michaela Bowden
No Relationships to Disclose
 
David Paul Carbone
Honoraria - Bayer; Biothera; Boehringer Ingelheim; Clovis Oncology; Genentech/Roche; GlaxoSmithKline; MedImmune; Merck; Novartis; Pfizer; Synta
Consulting or Advisory Role - Bayer; Biothera; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; Genentech/Roche; GlaxoSmithKline; MedImmune; Merck; Novartis; Pfizer; Synta
Research Funding - Bristol-Myers Squibb
 
Suresh S. Ramalingam
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Genentech/Roche; Lilly/ImClone; Novartis
Travel, Accommodations, Expenses - AstraZeneca; EMD Serono; Pfizer